InhibRx is a clinical-stage biotechnology company developing a broad pipeline of novel biologic therapeutic candidates. The company utilizes diverse methods of protein engineering to address the specific requirements of complex target and disease biology, including its proprietary sdAb platform, which enables the construction of molecules that contain multiple binding units with defined valency or multiple specificities. Its pipeline is focused on oncology, orphan diseases, and infectious diseases.